Search results for #Fruquintinib
#GISeries: Here we🗣️about the @US_FDA approval of #Fruquintinib from #FRESCO2 & how it fits in our Rx paradigm w/@adasarimd Full Int: - targetedonc.com/pivotal-practi… - oncbrothers.com/JC-FRESCO2 - Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter @TargetedOnc #crcsm
#Fruquintinib is currently approved for adults with metastatic #ColorectalCancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Learn more: ow.ly/3pxW50R9rgQ
This lovely keepsake arrived. I want to 🙏🏻 @VUMCDiscoveries and my colleagues for nominating me for the 2023 Biomedical Science Impact Award for my contribution to @TheLancet re: FRESCO-2 and the FDA approval of #fruquintinib with @adasarimd. #cancerResearch #cancer
The NMPA Accepts @hutchmed and Innovent’s NDA for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer #hutchmed #innovent #fruquintinib #sintilimab #endometrialcancer #regulatory #nmpa #ndanewdrugapplication #phase2 pharmashots.com/17168/the-nmpa…
📢 As #ColorectalCancer Awareness Month comes to an end, check out our top posts of the month focused on new advancements for this malignancy. #1: @CathyEngMD reviews FRESCO-2, which analyzed #fruquintinib for refractory metastatic colorectal cancer: buff.ly/3PjZtIE
.@CathyEngMD explains how results of the FRESCO-2 study led to the FDA's approval of #fruquintinib in the third-line setting for #colorectalcancer. Learn more about how fruquintinib differs from other VEGFR inhibitors: buff.ly/3PjZtIE #colorectalcancerAwarenessMonth
@GiOncNow @CathyEngMD Thank you Dr. @CathyEngMD for this amazing lecture. Also, I did not know anything about the drug #Fruquintinib but very fascinating how new drugs are evolving so fast and how helpful they are. @VUMCHemOnc . 🙌
💉 How does #fruquintinib compare to other treatments such as #bevacizumab for #colorectalcancer? @CathyEngMD discusses why fruquintinib may be a better treatment for some patients, especially for those with myelosuppression. Dr. Cathy Eng on FRESCO-2: buff.ly/3PjZtIE
#Fruquintinib plus paclitaxel versus paclitaxel as second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma (FRUTIGA): A randomized, multicenter, double-blind, placebo-controlled, phase 3 study ascopubs.org/doi/abs/10.120…
進行 #胃がん の2次治療として経口TKIである #fruquintinib とパクリタキセルの併用療法は、パクリタキセル単剤よりも有意に無増悪生存期間を延長できることが中国の臨床試験で明らかになりました。ただし全生存期間の延長は認められませんでした。 medical.nikkeibp.co.jp/leaf/all/cance…
#HCM Hutchmed's fruquintinib trial for gastric cancer shows promise! Patients who received fruquintinib plus paclitaxel had longer survival (5.6 months) compared to paclitaxel alone (2.7 months). #GastricCancer #PromisingResults #Fruquintinib
China's #fruquintinib is indeed the best price in the world. Because it's a new drug invented by a Chinese pharmaceutical company, the Chinese government has given great support, and there are very many patients in China, so the average price is very nice. facebook.com/share/p/Ax87Uc…
Summary of 5 new drugs/indications in GI malignancies that were @FDAOncology @US_FDA approved in 2023: - #Tucatinib - Mountaineer - #TAS102 + #Bevacizumab - Sunlight - #Pembro + Cis/Gem - KN966 - #Fruquintinib - FRESCO2 - #Pembro + Chemo - KN859 #OncTwitter #gism #crcsm
Summary of 5 new drugs/indications in GI malignancies that were @FDAOncology @US_FDA approved in 2023: - #Tucatinib - Mountaineer - #TAS102 + #Bevacizumab - Sunlight - #Pembro + Cis/Gem - KN966 - #Fruquintinib - FRESCO2 - #Pembro + Chemo - KN859 #OncTwitter #gism #crcsm https://t.co/RduaJ9F3LD
15. #Fruquintinib (#Fruzaqla) licensed to Takeda $TAK by Hutchmed (和黄医药) Indication: Metastatic colorectal cancer Stage: FDA approved on November 8, 2023 Date: January 23, 2023 Deal Size: Up to $1.13B: $400M upfront, milestones, royalties. 16/17 tinyurl.com/3st2wjdh
Fruzaqla For refractory, metastatic colorectal #cancer. #Fruquintinib inhibits VEGFRs 1, 2, and 3, halting endothelial cell functions and preventing tumor cell proliferation. A major breakthrough in cancer #treatment! 💊👩⚕️ #Fruzaqla #MedicalInnovation
HUTCHMED announces that Takeda receives U.S. FDA approval of FRUZAQLA (fruquintinib) for previously treated metastatic colorectal cancer. Here comes the related building blocks we can provide: buff.ly/49QcAKg #FRUZAQLA #fruquintinib #VEGFR #inhibitors #mCRC
